BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

...that indication are associated with upregulation of folate receptors, for which it has developed a TumorTag; folate receptors are...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer. ImmunoGen Inc. (NASDAQ:IMGN) expects data next year from the...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

ImmunoGen has been signaling for months that it would soon strike a licensing deal in China for its lead antibody-drug conjugate. On Monday, the biotech said Huadong will gain the program’s rights for $40 million...
BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jun 27, 2019
Company News

Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab

Immunogen is gutting its workforce and shelving at least two early stage programs to focus on the asset that put the biotech in this precarious position in the first place, antibody-drug conjugate mirvetuximab soravtansine. ImmunoGen...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 15, 2019
Company News

ImmunoGen looks to next Phase III after FDA rebuffs accelerated approval path for mirvetuximab

ImmunoGen plans to start a second Phase III trial before year end of mirvetuximab soravtansine that will focus on ovarian cancer patients with high FOLR1 expression after FDA told the company that data from a...
BioCentury | Mar 8, 2019
Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen lost $2.21 (47%) to $2.51 on March 1 after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian...
Items per page:
1 - 10 of 166